Transcept Pharmaceuticals
Richmond
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $40.0M
- Funding stage: M&A
- Last round: Series D (Mar 2007)
- Ticker: nasdaq:TSPT
- Website: transoral.com
- Phone: +1 510-215-3500
Industries & Categories
Biotechnology, Neuroscience, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/transcept-pharmaceuticals-1734444 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.